Skip to main content
. 2019 Jan 30;9(4):1029–1046. doi: 10.7150/thno.29868

Figure 10.

Figure 10

Labeling to evaluate OX6 and tumor necrosis factor (TNF) levels in the spleen at 90 days post-TBI. Treatment with moderate and high doses of stem cells appeared to modulate the exacerbated inflammatory response and downregulate OX6 (green) and TNF (red) expressions in the spleen 90 days post-TBI. n = 12 animals for each group. a: sham-control; b: TBI-vehicle; c: TBI-low dose; d: TBI-moderate dose; e: TBI-high dose. (A) Arrow heads indicate TNF-positive and OX6-positive cells. Scale bar = 50 µm. Magnification: 20×; 40× (inset). (B) TNF-positive cell count in the spleen. The sham group had significantly fewer TNF-positive cells than the vehicle group (*p<0.05). The moderate and high dose groups had significantly fewer TNF-positive cells than the vehicle group (**p<0.01; ***p<0.001). (C) OX6-positive cell count in the spleen. The sham group had significantly fewer OX6-positive cells than the vehicle (***p<0.001) and low dose (*p<0.05) groups. The moderate and high dose groups had significantly fewer OX6-positive cells than the vehicle group (*p<0.05; **p<0.01).